SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

Ra Kim, So; Lee, Sang‐Guk; Hyun Kim, Soo; Hee Kim, Jin; Hee Kim, Jin; Choi, Eunhye; Cho, Wonhee; Hoon Rim, John; Hwang, Inhwa; Joo Lee, Chan; Lee, Minyoung; Oh, Chang‐Myung; Y. Jeon, Justin; Yung Gee, Heon; Kim, Jeong-Ho; Kim, Jeong-Ho; Lee, Byung‐Wan; Seok Kang, Eun; Cha, Bong-Soo; Lee, Myung‐Shik; Yu, Je‐Wook; Won Cho, Jin; Kim, Jung‐Sun; Kim, Jung‐Sun; Lee, Yong‐ho

doi:10.1038/s41467-020-15983-6

Public

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

Published in Nature Communications • May 1, 2020

Authors:

So Ra Kim

Sang‐Guk Lee

Soo Hyun Kim

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent interleukin (IL)-1β release induces athe...

Subject

Inflammasome

Sulfonylurea

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!